TY - JOUR AU - Murphy, Conor F. AU - Roux, Carel W. le PY - 2018 TI - Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events? JF - Annals of Translational Medicine; Vol 6, No 10 (May 26, 2018): Annals of Translational Medicine (Focus on “Translational Neurodegeneration”) Y2 - 2018 KW - N2 - Several randomised controlled trials (RCTs) have proven the efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA), such as liraglutide, in both improving glycaemic control, inducing sustained significant weight loss, and reducing mortality in patients with diabetes. These benefits have been demonstrated in myriad cohorts, as patients with type 2 diabetes (T2D), prediabetes and normoglycemia all exhibit positive outcomes (1-4). UR - https://atm.amegroups.org/article/view/18783